Changes to the Patented Medicine Prices Review Board (PMPRB) regime, contained in pending amendments to the Patented Medicines Regulations, have been delayed until January 1, 2022. These amendments form the basis for new PMPRB Guidelines, which are scheduled to come into force at the same time as the amendments.

The amendments contain a number of changes affecting the PMPRB's review of patented medicine prices. These include new mandatory factors to be considered by the Board, such as pharmacoeconomic value; a requirement to include "adjustments" when computing average transaction prices reported to the Board; and a revised basket of international comparator countries for reference pricing that omitted the United States and Switzerland.

As we reported, the amendments were introduced in August 2019. At that time, they were set to come into force on July 1, 2020. The coming-into-force date of the amendments has since been delayed three times: first to January 1, 2021, then to July 1, 2021, and most recently to January 1, 2022. In addition, the coming-into-force date of the amendment regarding average transaction prices has been delayed to an unspecified future date, pending the outcome of litigation regarding its validity.

The RIAS indicates that the purpose of the most recent six-month delay to the amendments is "to provide industry stakeholders with additional time to adapt to the new reporting obligations given the unexpected impact of the third wave of the COVID-19 pandemic."

These amendments are separate from recent changes that bring Certificates of Supplementary Protection (CSPs) into the PMPRB regime, which came into force on June 30, 2021.

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.